key: cord-0023376-ij6ixmlo
authors: Xin, Xiao-Yu; Lai, Ze-Hua; Ding, Kai-Qi; Zeng, Li-Li; Ma, Jian-Fang
title: Angiotensin-converting enzyme polymorphisms AND Alzheimer’s disease susceptibility: An updated meta-analysis
date: 2021-11-24
journal: PLoS One
DOI: 10.1371/journal.pone.0260498
sha: 1fc82cb213afe61ea0f75cd9b29e1966089d6f91
doc_id: 23376
cord_uid: ij6ixmlo

BACKGROUND: Many studies among different ethnic populations suggested that angiotensin converting enzyme (ACE) gene polymorphisms were associated with susceptibility to Alzheimer’s disease (AD). However, the results remained inconclusive. In the present meta-analysis, we aimed to clarify the effect of ACE polymorphisms on AD risk using all available relevant data. METHODS: Systemic literature searches were performed using PubMed, Embase, Alzgene and China National Knowledge Infrastructure (CNKI). Relevant data were abstracted according to predefined criteria. RESULTS: Totally, 82 independent cohorts from 65 studies were included, focusing on five candidate polymorphisms. For rs1799752 polymorphism, in overall analyses, the insertion (I) allele conferred increased risk to AD compared to the deletion (D) allele (I vs. D: OR = 1.091, 95% CI = 1.007–1.181, p = 0.032); while the I carriers showed increased AD susceptibility compared with the D homozygotes (II + ID vs. DD: OR = 1.131, 95% CI = 1.008–1.270, p = 0.036). However, none of the positive results passed FDR adjustment. In subgroup analysis restricted to late-onset individuals, the associations between rs1799752 polymorphism and AD risk were identified using allelic comparison (OR = 1.154, 95% CI = 1.028–1.295, p = 0.015, FDR = 0.020), homozygotes comparison, dominant model and recessive model (II vs. ID + DD: OR = 1.272, 95% CI = 1.120–1.444, p < 0.001, FDR < 0.001). Nevertheless, no significant association could be revealed after excluding studies not in accordance with Hardy-Weinberg equilibrium (HWE). In North Europeans, but not in East Asians, the I allele demonstrated increased AD susceptibility compared to the D allele (OR = 1.096, 95% CI = 1.021–1.178, p = 0.012, FDR = 0.039). After excluding HWE-deviated cohorts, significant associations were also revealed under homozygotes comparison, additive model (ID vs. DD: OR = 1.266, 95% CI = 1.045–1.534, p = 0.016, FDR = 0.024) and dominant model (II + ID vs. DD: OR = 1.197, 95% CI = 1.062–1.350, p = 0.003, FDR = 0.018) in North Europeans. With regard to rs1800764 polymorphism, significant associations were identified particularly in subgroup of European descent under allelic comparison (T vs. C: OR = 1.063, 95% CI = 1.008–1.120, p = 0.023, FDR = 0.046), additive model and dominant model (TT + TC vs. CC: OR = 1.116, 95% CI = 1.018–1.222, p = 0.019, FDR = 0.046). But after excluding studies not satisfying HWE, all these associations disappeared. No significant associations were detected for rs4343, rs4291 and rs4309 polymorphisms in any genetic model. CONCLUSIONS: Our results suggested the significant but modest associations between rs1799752 polymorphism and risk to AD in North Europeans. While rs4343, rs4291 and rs4309 polymorphisms are unlikely to be major factors in AD development in our research.

Introduction genotype is regarded as a determinant of ACE expression levels in plasma, cells and tissues. Approximately 50% variability in plasma levels of ACE depends on the rs1799752 polymorphism [9, 10] . Individuals carrying the D allele have higher plasma ACE levels compared to I homozygotes [11] . Moreover, rs1799752 I/D polymorphism has been reported to link with coronary heart disease and cognitive impairment, for example, AD and vascular dementia (VD). Besides rs1799752 I/D polymorphism, several other polymorphisms of the ACE gene were also investigated in AD cohorts of different ethnics, such as rs1800764 T/C, rs4343 A/G, rs4291 A/T polymorphisms, et al. rs1800764 and rs4291 located in the regulatory region of ACE gene, while rs4343 in the exotic region. Though some studies have demonstrated the associations, inconsistency was still presented among different study populations. These discrepancies may be related to the small sample size of individual studies, the difference in ethnic background and the different methodologies used for analysis. While meta-analysis is a wellestablished means to quantitatively synthesize all association data across studies to reduce heterogeneity and identify minor genetic effects, which largely addressing the issue of sample size.

Thus, in the present study, we performed an updated meta-analysis combining all available case-control studies to derive a more precise estimation of the associations between ACE gene polymorphisms and AD susceptibility. We also stratified the study cohorts, when possible, according to the age of onset and ethnic background. Since some recent evidence suggested that the presence of APOE ε4 influence the behavioural effects of ACE I/D polymorphism in AD, and the protective effects of ACE inhibitors or angiotensin receptor blockers on cognitive decline correlated with APOE ε4 carrier status, we also performed subgroup analyses according to APOE ε4 carrier status if sufficient data could be obtained [12, 13] .

We performed computerized searches of PubMed, Embase, Alzgene and China National Knowledge Infrastructure (CNKI) up to January 31 st , 2021. The following keywords were used: (angiotensin-converting enzyme or ACE or DCP1) AND (Alzheimer or dementia) AND (polymorphism or variant or allele or genotype), with no language restriction. In addition, references of retrieved articles, reviews and meta-analyses were checked manually for potential studies.

Studies included in the meta-analysis should meet the following criteria: (1) case-control design; (2) the evaluation of the relationship between the ACE polymorphisms and AD; (3) AD was diagnosed according to generally accepted criteria, such as criteria of the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) or of the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV), et al.; (4) genotype or allele frequencies were available in both cases and controls. Studies that performed in more than 1 population were considered as separate investigations. When the articles contained duplicated data, the most recent or complete data set was selected. Since all the included studies were gene polymorphism investigations in patients and controls, which were not suitable for randomized controlled design, no randomized controlled trial (RCT) could be identified and involved in our research.

Data were extracted from the eligible articles by two investigators independently and agreements were achieved on all items. The following information was collected using a predefined reporting form: name of the first author, publication year, sample size, country, racial descent, diagnosis criteria of AD, genotyping method, source of controls, distribution of allele and genotypes in both AD and control groups, and Hardy-Weinberg equilibrium (HWE) in controls. The Newcastle-Ottawa Scale (NOS) was performed to assess the methodological quality of the included studies. The total NOS score ranges from 0 to 9. If the score was 6 or more, the study was assumed to be high quality [14] .

The STATA Software (version 14.0, Stata Corp) was used for analytical procedures. Hardy-Weinberg equilibrium (HWE) was assessed in the controls using the exact test. For each gene polymorphism, meta-analysis was performed only if data were available from at least 4 independent studies. We did not assume a genetic model in advance. Firstly, odds ratio was produced by allelic comparison. Secondly, we compared each genotype with one other in turn. Thirdly, we compared each genotype in turn with the other two combined. All these three methods have been widely used for pooling data in genetic association studies [15] .

The strength of association was determined by pooled odds ratio (OR) along with the corresponding 95% confidence interval (CI). The Dersimonian and Laird's Q test was performed for heterogeneity evaluation. If the p value was less than 0.10, the heterogeneity was considered statistically significant. Quantification of the heterogeneity was assessed using the I 2 metric, which represents the percentage of the observed between study variabilities due to heterogeneity rather than due to chance. I 2 ranges from 0% to 100%, with higher values indicating a greater degree of heterogeneity. Where there was significant heterogeneity among studies (I 2 �50%), the pooled OR was calculated by a random-effect model (Dersimonian and Laird); Otherwise, a fixed-effect model was used (Mantel-Haenszel).

Stratified analysis was performed, when feasible, by geographic location, age of onset, or APOE ε4 status. In addition, pooled odds ratios were calculated particularly in large sample size cohorts (�300 participants). Cumulative meta-analysis was conducted to investigate the trend and the stability of risk effects as evidence accumulated over time. To adjust for multiple comparisons, we applied the Benjamini-Hochberg (BH) method to control false discovery rate (FDR) [16] . Publication bias was examined using both the Begg-Mazumdar test and the Egger's regression asymmetry test.

Eligible studies and candidate polymorphisms 77 articles covered 35 polymorphisms were identified as potential candidates after primary electronic searches and manual screening. Among these, 9 articles were excluded for duplicated data. 2 articles were excluded since there was no sufficient number of studies for a metaanalysis (more than four separate studies were required for a meta-analysis in the present investigation) [17, 18] . For 1 instance, because exact allele or genotype counts could not be obtained despite attempts to contact the authors, it was also not involved [19] . Therefore, 65 articles with 82 samples were finally included in our study, focusing on 5 polymorphisms as following: rs1799752 I/D, rs1800764 T/C, rs4343 A/G, rs4291 A/T, rs4309 C/T ( Table 1 ). The mean number of samples per candidate polymorphism was 24.80 ± 19.49 (Table 2) . Main diagnostic criteria for AD included NINCDS-ADRDA, DSM-IV, ICD-10, CREAD. All the included studies used standard genotyping method in laboratory. Fig 1. shows the detailed screening process for the involved literature. 

Totally, 57 samples were found dealing with rs1799752 polymorphism and AD risk, comprising 8619 cases and 15718 controls. Since 1 sample just provided allele counts, it was only analyzed in the allelic comparison [74] . In overall analyses, the associations between rs1799752 polymorphism and AD susceptibility were identified under allelic comparison (I vs. D: OR = 1.091, 95% CI = 1.007-1.181, p = 0.032) and dominant model (II + ID vs. DD: OR = 1.131, 95% CI = 1.008-1.270, p = 0.036). However, the FDR values were both higher than 0.05, suggesting that the associations were not reliable. Sensitivity analysis by excluding studies not in accordance with HWE obtained similar results (Table 3 ). When analyses were performed particularly in investigations published in English, no reliable associations were identified either. In subgroup analysis restricted to late-onset individuals, our investigation indicated significant associations between rs1799752 polymorphism and risk to AD using allelic comparison, additive model (II vs. ID, II vs. DD), dominant model and recessive model (II vs. ID + DD). In brief, rs1799752 I conferred increased risk to AD compared to the D allele with an odds ratio of 1.154 (95% CI = 1.028-1.295, p = 0.015, FDR = 0.020). In genotype analysis, the I homozygotes showed higher susceptibility for developing AD compared to the D homozygotes (OR = 1.308, 95% CI = 1.120-1.528, p = 0.001, FDR = 0.003). Moreover, the risk for AD was significantly higher in the I homozygotes than in the D carriers (OR = 1.272, 95% CI = 1.120-1.444, p < 0.001, FDR < 0.001, Fig 2) . In cumulative meta-analysis for the I homozygotes versus the D homozygotes, after only 3 of the 18 cohorts had been studied, the fixed-effect odds ratio became larger than 1 and remained so thereafter (Fig 3) . However, after excluding 3 cohorts deviated from HWE [30, 31, 55], no positive results could be identified in any genetic model. Subgroup analyses of large sample size cohorts and small sample size cohorts obtained similar results.

We also compared ethnic difference among East Asians (Chinese and Japanese), North Europeans and populations of South European descent (Mediterranean and Middle Eastern). Respectively, 15 studies carried out among East Asians, 16 among North Europeans and 18 in cohorts of South European descent. East Asians had higher I allele frequency compared to those of European descent (p < 0.001). In East Asians, the significant associations between rs1799752 and AD susceptibility were revealed using allelic comparison, additive model (II vs. ID, II vs. DD), and recessive model. Nevertheless, none of them was robust enough to withstand the FDR adjustment, suggesting the positive results were weak evidence of true associations. In North Europeans, the I allele conferred increased risk to AD compared to the D allele (OR = 1.096, 95% CI = 1.021-1.178, p = 0.012, FDR = 0.039). Meanwhile, the I homozygotes Fig 4) . With regard to populations of South European descent, no significant association was found under all comparisons (Table 4) .

Seven studies provided data about rs1799752 polymorphism and ε2/ε3/ε4 genotypes. With regard to AD susceptibility, no significant association was identified in both APOE ε4 positive and negative subgroups. However, after exclusion of HWE-deviated samples [27, 51] , in the I homozygotes and the D homozygotes, the presence of APOE ε4 increased the risk of AD 2.84-fold (95% CI = 1.825-4.418, p < 0.001) and 7.06-fold (95% CI = 3.963-12.571, p < 0.001), respectively.

Analysis for rs1800764 T/C polymorphism was available on 20 samples, including 6371 cases and 6768 controls. All the above investigations were published in English. In total, the T Fig 5) . No significant association was revealed in all comparisons in late-onset subgroup analysis. Nevertheless, after excluding 2 cohorts not satisfying HWE [71] , all the associations became insignificant.

23 studies containing 9783 cases and 16890 controls studied the association between rs4343 A/ G polymorphism and AD risk. 20 studies including 5973 cases and 13044 controls evaluated the correlation of rs4291 A/T polymorphism and AD susceptibility. For rs4309 C/T, 4 studies involving 1187 cases and 1056 controls were included. All of those investigations were 

Both the Begg-Mazumdar test and the Egger's regression asymmetry test were conducted to evaluate potential publication bias. For all the above polymorphisms, the p values of Begg-Mazumdar tests and Egger's tests were greater than 0.05, suggesting no evidence was found for the presence of publication bias.

In this comprehensive meta-analysis about ACE polymorphisms and AD susceptibility on the basis of all available updated studies published in both Chinese and English, 82 cohorts were involved, comprising more than 47000 genotyped cases and controls. Our results demonstrated the significant associations between rs1799752 polymorphism and AD susceptibility in 

Each study was used as an information step. The vertical dotted line is the summary odds ratio. Bars, 95% confidence interval (CI).

https://doi.org/10.1371/journal.pone.0260498.g003

North Europeans, but not in East Asians and populations of South European descent, suggesting the ethnic difference of the role that rs1799752 polymorphism played on AD risk. However, our results did not support the associations between rs4343, rs4291 and rs4309 polymorphisms and susceptibility to AD. Meta-analysis has been considered as a useful tool to achieve more precise estimation of the effect of candidate polymorphism in multifactorial diseases, such as AD. Small sample size, in combination with modest effect, might lead to low statistical power of individual study, which is the most likely explanation for the controversial results of previous investigations. Metaanalysis is one strategy to increase sample size in an attempt to reduce random error which might produce false-positive or false-negative associations. Since deviation from HWE usually means mistyping or selection bias [85] , we also excluded those samples not satisfying HWE in controls in sensitivity analysis to increase the accuracy of our results.

For rs1799752 polymorphism, compared to previous meta-analyses performed in 2004 and 2005 [49, 86], we included more than 20 new studies and covered all articles published in Chinese. In overall analyses, before multiple comparison adjustment, our study indicated that the I allele conferred increased risk to AD compared with the D allele and the D homozygotes were at reduced risk of AD compared to the I carriers, which were in accordance with results from the two previous meta-analyses. To avoid false positive in multiple comparisons, we applied the widely accepted FDR adjustment in our study [87] . Since no significant association passed the FDR adjustment, we believed that the associations were not robust enough. In another investigation adopted false-positive report probability (FPRP) to control false-positive findings, the authors obtained similar results as those from our study [88] .

In subgroup analysis, significant associations between rs1799752 polymorphism and lateonset AD risk were revealed using allelic comparison, additive model, dominant model and recessive model. However, as well as those identified for rs1800764 in populations of European descent, after excluding studies not satisfying HWE, no positive results could be obtained, indicating the instability of the associations. Thus, in the future, well-designed large sample size studies to provide more forceful evidence for the possible associations are required.

When cohorts were stratified by ethnic background, significant difference was identified among East Asians, North Europeans and populations of South European descent with regard to rs1799752 polymorphism. East Asians had higher I allele frequencies compared to populations of European descent in controls. Furthermore, the most robust and consistent associations between rs1799752 polymorphism and risk to AD were identified particularly in North Europeans. We attributed the difference of results among Europeans and Asians mainly to the difference of genetic background. However, no comparable investigations have been carried out with regard to mechanisms underlying rs1799752 polymorphism and AD development between different ethnics, which still need further research to clarify. Before FDR adjustment, our results of East Asians were in accordance with those of previous meta-analysis performed in Chinese samples [89] . The ethnic difference of the associations between rs1799752 polymorphism and AD risk should be considered in the design of future studies.

One copy of the APOE ε4 allele may increase the risk of AD by 2-6 times [90]. In our study, in the D homozygotes, the presence of APOE ε4 increased the risk of AD around 7.06-fold, much higher than that identified in the I homozygotes. However, only 5 studies satisfying HWE provided data about rs1799752 polymorphism and APOE ε4 status, we still need more information to draw safe conclusions about the possible interaction between APOE ε4 and rs1799752 polymorphism. In overall analyses for rs1799752 polymorphism, high heterogeneity was identified in different comparisons. After ethnic stratification, high heterogeneity was removed in both North Europeans and cohorts of South European descent, but not in East Asians, suggesting the existence of other confounding factors responsible for heterogeneity. Besides ethnic background, other sources accounting for heterogeneity include differences in sample selection (e.g., age of onset, diagnosis criteria), or in methods (e.g., genotyping methods), or it may be due to interaction with other risk factors (e.g., APOE ε4 status). When we restricted the study populations to late-onset individuals, heterogeneity among studies reduced. While stratification by APOE ε4 status nearly removed all the heterogeneity. Our results suggested that age of onset and interaction with APOE ε4 status also contributed to the high heterogeneity in the analyses of rs1799752 polymorphism.

There are several limitations of our investigation. Firstly, publication bias against reporting negative associations might affect our results. Secondly, no other language article regarding ACE polymorphisms and risk to AD was found besides those in English and Chinese. However, some articles cloud be published in journals not on the international journal catalogs, leading to potential language bias. Thirdly, owing to lack of original data, further adjustments by other covariables, such as gender or cardiovascular complications, could not be performed.

In summary, ACE rs1799752 polymorphism is associated with risk to AD in North Europeans. The relationships between rs1799752 and late-onset AD susceptibility, as well as rs1800764 and AD risk in populations of European descent, still need further studies to illustrate. While rs4343, rs4291 and rs4309 polymorphisms are unlikely to be major factors in AD development in our research.

Supporting information S1 Checklist. PRISMA 2020 checklist.

(DOCX)

Data curation: Xiao-Yu Xin, Ze-Hua Lai. 

Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study

Alzheimer's disease

Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches

Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer's disease: a systematic review and meta-analysis

Apolipoprotein E in Alzheimer's disease and other neurological disorders

Targeting amyloid clearance in Alzheimer's disease as a therapeutic strategy

A clinical dose of angiotensin-converting enzyme (ACE) inhibitor and heterozygous ACE deletion exacerbate Alzheimer's disease pathology in mice

Peripherally derived angiotensin converting enzyme-enhanced macrophages alleviate Alzheimer-related disease

Angiotensin System Polymorphisms' in SARS-CoV-2 Positive Patients: Assessment Between Symptomatic and Asymptomatic Patients: A Pilot Study

Angiotensin converting enzyme: A review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection

ACE I/D Polymorphism, Plasma ACE Levels, and Long-term Kidney Outcomes or all-cause death in patients with type 1 diabetes

Behavioural effects of the ACE insertion/deletion polymorphism in Alzheimer's disease depend upon stratification according to APOE-ε4 carrier status

The use of angiotensin-converting enzyme inhibitors vs. angiotensin receptor blockers and cognitive decline in Alzheimer's disease: the importance of blood-brain barrier penetration and APOE ε4 carrier status

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

Association of angiotensin converting enzyme activity and angiotensin converting enzyme gene polymorphism with vascular dmentia and Alzheimer's disease

Angiotensin converting enzyme insertion/deletion polymorphism in sporadic and familial Alzheimer's disease and longevity. Arch Gerontol Geriatr

Haplotypes across ACE and the risk of Alzheimer's disease: the three-city study

Association of apoE gene, A2M gene and ACE gene polymorphism with Alzheimer's disease

ACE I/D polymorphism in Alzheimer's disease

Genetic analysis of Alzheimer's disease in the Uppsala Longitudinal Study of Adult Men

An age effect on the association of common variants of ACE with Alzheimer's disease

Plasma angiotensin-converting enzyme in Alzheimer's disease

Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals

Examination of the current top candidate genes for AD in a genome-wide association study

Amyloid-beta-related genes SORL1 and ACE are genetically associated with risk for late-onset Alzheimer disease in the Chinese population

An association study of 21 potential Alzheimer's disease risk genes in a Finnish population

Intermediate phenotypes identify divergent pathways to Alzheimer's disease

A multi-center study of ACE and the risk of late-onset Alzheimer's disease

No replication of genetic association between candidate polymorphisms and Alzheimer's disease

A pilot study of gene/ gene and gene/environment interactions in Alzheimer disease

Genetic influences on Alzheimer's disease: evidence of interactions between the genes APOE, APOC1 and ACE in a sample population from the South of Brazil

Association of Angiotensin-converting enzyme insertion (I)/deletion (D) genotype in Alzheimer's disease patients of north Indian population

Angiotensin-converting enzyme gene and plasma protein level in Alzheimer's disease in Taiwanese

The association between angiotensin converting enzyme gene polymorphism and Alzheimer's disease in Jiamusi region

Relationship between the gene polymorphisms of kallikrein-kinin system and Alzheimer's disease in a Hunan Han Chinese population

Association between ACE polymorphism, cognitive phenotype and APOE E4 allele in a Tunisian population with Alzheimer disease

Association between an angiotensin-converting enzyme gene polymorphism and Alzheimer's disease in a Tunisian population

Association between ACE gene polymorphisms and Alzheimer's disease in Han population in Hebei Peninsula

Association Study of angiotensin converting enzyme with Alzheimer's Disease and mild cognitive impairment

Genetic factors associated with the predisposition to late onset Alzheimer's disease

Relationship between angiotensin converting enzyme gene polymorphism and Alzheimer's disease in elderly patients of Nanjing

Hardy Weinberg Equilibrium Disturbances in Case-Control Studies Lead to Non-Conclusive Results

Alzheimer disease risk and genetic variation in ACE: a meta-analysis

Strategies in adjusting for multiple comparisons: A primer for pediatric surgeons

Angiotensin-converting enzyme insertion/ deletion polymorphism is not a major determining factor in the development of sporadic Alzheimer disease: evidence from an updated meta-analysis

Angiotensin-converting enzyme gene insertion-deletion polymorphism is a risk marker for Alzheimer's disease in a Chinese population: a meta-analysis of case-control studies